US OptionsDetailed Quotes
NVS250516C130000
- 0.05
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume20 Open Interest130.00Strike Price0.00Turnover33.87%IV13.79%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0199Delta0.0069Gamma2285.80Leverage Ratio-0.0134Theta0.0007Rho45.52Eff Leverage0.0100Vega
Novartis AG Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ Follow Linkedin posts by Esperion. $Novartis AG (NVS.US)$ is connected. I expect to hear a Big partnership or acquistion. The stock price is extremely undervalued.
1
3
$Total Return Securities Fund (SWZ.US)$ In November 2024, Novartis and Ratio Therapeutics entered into a worldwide licence and collaboration agreement worth $745m to advance a somatostatin receptor 2 (SSTR2)-targeting radiotherapeutic candidate for cancer.
Morning Movers
Gapping Up
$MSP Recovery (MSPR.US)$ shares surged 125% after the company announced a strategic term sheet aimed at enhancing liquidity and restructuring current agreements. This move will eliminate over $1.2 billion in corporate guaranteed debt and includes new agreements designed to propel future growth.
$JPMorgan (JPM.US)$ climbed 3.8% in premarket trading on Friday after the bank reported a quarterly profit increa...
Gapping Up
$MSP Recovery (MSPR.US)$ shares surged 125% after the company announced a strategic term sheet aimed at enhancing liquidity and restructuring current agreements. This move will eliminate over $1.2 billion in corporate guaranteed debt and includes new agreements designed to propel future growth.
$JPMorgan (JPM.US)$ climbed 3.8% in premarket trading on Friday after the bank reported a quarterly profit increa...
Expand 17
2
5
$Novartis AG (NVS.US)$ Has any received the Dividends? Can help to share
2
$Novartis AG (NVS.US)$
Groundbreaking FDA Approval: Novartis Drug Shows 36% Reduction in Severe Kidney Disease Symptoms
Groundbreaking FDA Approval: Novartis Drug Shows 36% Reduction in Severe Kidney Disease Symptoms
$Novartis AG (NVS.US)$
Breakthrough: Novartis Scores Historic FDA Approval for Rare Kidney Disease Treatment
Breakthrough: Novartis Scores Historic FDA Approval for Rare Kidney Disease Treatment
$Novartis AG (NVS.US)$ Only u are dropping
$Novartis AG (NVS.US)$ Finally moving up before Dividend
$Novartis AG (NVS.US)$ why this stock keeps falling despite so many good news. Can someone enlighten pls
$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
5
3
2
No comment yet
HH1000 : aren't they doing an offering. diluting shares. it's gonna make the price drop. no thanks for buying
Tonyco HH1000 :
DazzlerAus HH1000 : they are not necessarily doing an offering S3 expire it oretty standard for these conpanies to have a standing S3 in case its needed often it just insurance against an unexpected result ie if suddenly their main drug started resulting in bad side effects